ImmunityBio posts 168% revenue surge as ANKTIVA adoption accelerates
Share
ImmunityBio (NASDAQ:IBRX), a commercial-stage biotechnology firm, reported on April 9, 2026, that preliminary net product revenue for the first quarter reached approximately $44.2 million.
